The financials
Denali Therapeutics Inc. by the numbers
Denali Therapeutics Inc. (DNLI) reported revenue of $3.6M in Q2 2026 (quarter ended June 30, 2026). That came with a gross margin of 97% and net loss of $128M. For the full year FY2025, revenue was $0 and net income −$513M. Its largest product in 2023-Q2 was ATV Abeta Program License at $294M, 100% of the disclosed total, just ahead of Option Services at 0.1%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.6M | $0 | n/a |
| Gross profit | $3.5M | $0 | n/a |
| Operating income | −$131M | −$135M | n/a |
| Net income | −$128M | −$124M | n/a |
| Diluted EPS | −$0.68 | −$0.72 | n/a |
| Product | Revenue | Share |
|---|---|---|
| ATV Abeta Program License | $294M | 100% |
| Option Services | $211K | 0.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2024Total $0.00
Option Services grew -100% year on year
Segment Latestyear on year
- ATV Abeta Program License$0.00$0.00year on year --
- CNS Program License$0.00$0.00year on year --
- Collaboration Agreement Services--year on year --
- Option Services$0.00$0.00year on year -100%-100%
- PTVPGRN Services$0.00$0.00year on year --